SAB Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Lead candidate SAB-142 advanced to phase II-B with strong phase I data and regulatory de-risking. Q1 2026 ended with $217.6M in cash, supporting operations through 2028. SAFEGUARD trial enrollment is on track, and a manufacturing deal with Emergent BioSolutions supports future commercialization.
-
SAB-142, a human anti-thymocyte globulin, is in Phase IIb for newly diagnosed type 1 diabetes, showing strong efficacy and safety advantages over existing therapies. The pivotal SAFEGUARD trial is progressing well, with robust financial backing and plans for broader autoimmune indications.
-
SAB-142, a fully human anti-thymocyte globulin, is in a pivotal Phase IIb trial for newly diagnosed type 1 diabetes, aiming to preserve beta cells with a superior safety and dosing profile compared to existing therapies. Top-line data are expected in the second half of 2027, with a strong cash runway and significant market potential.
-
SAB-142, a fully human anti-thymocyte immunoglobulin, is in a pivotal global trial for newly diagnosed Type 1 Diabetes, aiming to preserve beta cell function and enable chronic dosing without immunogenicity. Enrollment is set to finish by end of 2026, with data expected in 2027.
-
SAB-142, a fully human anti-thymocyte immunoglobulin, is in a pivotal global phase II-B trial for type 1 diabetes, showing strong safety and redosing advantages over competitors. The company is fully funded through 2028 and aims for significant market impact and future label expansion.
Fiscal Year 2025
-
A human anti-thymocyte immunoglobulin is advancing to a pivotal phase II-B trial for type 1 diabetes, aiming to offer durable efficacy without immunogenicity or lymphodepletion. Regulatory trends support C-peptide as an approval endpoint, and a significant commercial opportunity exists for this first-in-class therapy.
-
SAB-142, a human anti-thymocyte globulin, is advancing in a pivotal phase 2b trial for newly diagnosed type 1 diabetes, aiming to address safety and efficacy gaps left by Thymoglobulin. The FDA-endorsed Safeguard study targets a $5B+ market, with data expected in H2 2027.
-
A pivotal global phase 2b trial for a novel human IgG-based immunomodulator in type 1 diabetes is underway, targeting newly diagnosed patients and aiming for best-in-class efficacy and safety. The study is fully funded through 2028, with data expected in late 2027.
-
A proprietary bovine platform enables safe, redosable, fully human polyclonal IgG therapies for type 1 diabetes, with phase one data showing strong safety and mechanistic validation. The phase two Safeguard study targets newly diagnosed patients, aiming for C-peptide preservation, and the platform holds promise for broader autoimmune indications.
-
A novel human anti-thymocyte globulin platform using transchromosomic cows showed promising phase I safety and mechanistic data, including T-cell exhaustion and Treg sparing without long-term lymphodepletion. A 142-patient phase II study in type 1 diabetes will start mid-year, with interim data expected in a year.